- Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza
- 2 Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial
- 4 Benjamin J. Cowling^{1,2}, Sook-San Wong^{1,3}, Jefferson J. S. Santos⁴, Lisa Touyon^{1,3}, Jordan
- 5 Ort⁴, Naiqing Ye⁴, Natalie K. M. Kwok¹, Faith Ho¹, Samuel M. S. Cheng¹, Dennis K. M. Ip¹,
- Malik Peiris¹, Richard J. Webby⁵, Patrick C. Wilson⁶, Sophie A. Valkenburg^{3,7}, John S.
- 7 Tsang⁸, Nancy H. L. Leung^{1,2}, Scott E. Hensley⁴, Sarah Cobey⁹
- 9 Affiliations:

3

- 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
- Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
- 12 Special Administrative Region, China
- 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology
- 14 Park, New Territories, Hong Kong Special Administrative Region, China
- 15 3. HKU-Pasteur Research Pole, Li Ka Shing Faculty of Medicine, The University of Hong
- 16 Kong, Hong Kong Special Administrative Region, China
- 4. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,
- 18 Philadelphia, PA 19104
- 19 5. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN
- 20 38105
- 21 6. Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York,
- 22 NY 10021
- 7. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and
- 24 Immunity, University of Melbourne, Melbourne, Australia

- 8. Yale Center for Systems and Engineering Immunology and Department of Immunobiology,
- 26 Yale University School of Medicine, New Haven, CT 06520
- 9. Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637
- 29 **Corresponding author:**

33

38

- 30 Prof. Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The
- University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong
- 32 Tel: +852 3917 6711; Email: <u>bcowling@hku.hk</u>
- Word count (abstract): 312
- Word count (main text): 3,473
- Running head: Antibody responses after repeated influenza vaccination
- 37 Clinicaltrials.gov: NCT04576377

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

ABSTRACT Background: Studies have reported that repeated annual vaccination may influence the effectiveness of the influenza vaccination in the current season. The mechanisms underlying these differences are unclear but might include "focusing" of the adaptive immune response to older strains. Methods: We established a 5-year randomized placebo-controlled trial of repeated influenza vaccination (Flublok, Sanofi Pasteur) in adults 18-45 years of age. Participants were randomized equally between five groups, with planned annual receipt of vaccination (V) or V. Serum samples were collected each year just before vaccination and after 30 and 182 days. A subset of sera were tested by hemagglutination inhibition assays, focus reduction neutralization tests and enzyme-linked immunosorbent assays against vaccine strains. Results: From 23 October 2020 through 11 March 2021 we enrolled and randomized 447 adults. We selected sera from 95 participants at five timepoints from the first two study years for testing. Among vaccinated individuals, antibody titers increased between days 0 and 30 against each of the vaccine strains, with substantial increases for first-time vaccinees and smaller increases for repeat vaccinees, who had higher pre-vaccination titers in year 2. There were statistically significant reductions in the proportion of participants achieving a four-fold greater rise in antibody titer for the repeat vaccinees for A(H1N1), B/Victoria and B/Yamagata, but not for influenza A(H3N2). There were no statistically significant differences between groups in geometric mean titers at day 30 or the proportions of participants with antibody titers ≥ 40 at day 30 for any of the vaccine strains. **Conclusions:** In the first two years, repeat vaccinees and first-time vaccinees had similar post-vaccination geometric mean titers to all four vaccine strains, indicative of similar levels

of clinical protection. The vaccine strains of A(H1N1) and A(H3N2) were updated in year 2,

		•		11 . 1 .	. 1		
65	nroviding an	n opportunity to ex	inlore antigenic	distances het	ween those (straine in	hiimang in
00	providing an	i opportunity to ch	ipiore unugeme	distances bet	WCCII tilosc i	ou anno m	iiuiiiuiib iii

subsequent years.

67

69

68 Key words: influenza; vaccination; immunogenicity; antibody

INTRODUCTION

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

The efficacy of influenza vaccines has been demonstrated in randomized trials, and annual influenza vaccination campaigns prevent considerable morbidity and mortality [1]. Continuous viral evolution necessitates regular updates to vaccine strains, and the degree of match between vaccine and circulating strains affects vaccine protection [2]. A number of studies have reported that repeated annual vaccination may influence the effectiveness of the influenza vaccination in the current season [3-7]. The effect of repeated vaccination on immunogenicity has been less frequently assessed in multi-year randomized trials, but repeat vaccination effects are also observed [8-12]. The mechanisms underlying these differences are unclear, but might include "focusing" of the adaptive immune response to older strains [13]. Under this model, repeated exposures boost responses to conserved and potentially less protective epitopes, which might in some years reduce protection against circulating strains [14, 15]. Enhanced influenza vaccines, including the recombinant hemagglutinin vaccine Flublok (Sanofi Pasteur), stimulate stronger immune responses and may be able to overcome repeat vaccination effects. The Flublok vaccine has two major differences with the standard egggrown inactivated influenza vaccine [10, 16, 17]. First, because eggs are not used in the production process for Flublok, the antigens included in the vaccine are more similar to circulating viruses, circumventing the issue of egg-adapted mutations in the hemagglutinin (HA) protein that can lead to antigenic mismatch [10, 18]. Second, it includes three times more HA antigen than standard-dose vaccines and can therefore generate a stronger, more HA-specific humoral immune response [10, 11]. Flublok has been approved by the Food and Drug Administration for use in the United States in all adults ≥18 years of age since October 2014 [19]. Evidence from randomized trials have shown improved immunogenicity and

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

efficacy and a slightly lower local reactogenicity compared with standard inactivated influenza vaccine in adults ≥18 years [20]. We designed a randomized controlled trial to explore immune responses to first-time or repeated influenza vaccination with the Flublok vaccine, with a particular interest in the possible occurrence of repeat vaccination effects. **METHODS** Study design This study is a randomized controlled trial in adults 18-45 years of age at enrolment (Clinicaltrials.gov: NCT04576377). Participants were enrolled from the general community in Hong Kong, with study advertisements distributed via institutions (such as schools and universities), organizations (such as professional associations), and local community centers, and through mass promotion efforts including mass mailing to residential estates, advertisements in newspapers and public transport, social media platforms (such as Facebook), bulk emails, and invitation to and referrals from members of previous studies. Individuals were eligible to participate if they were between 18 and 45 years of age, capable of providing informed consent, and intending to reside in Hong Kong for at least the next two years. Potential participants were excluded if they had been vaccinated against influenza in the preceding 24 months, if they were included in a priority group for influenza vaccination (e.g. healthcare worker, pregnant woman), if they had a diagnosed immunosuppressive condition or were taking immunosuppressive medication, or if they had severe allergies or bleeding conditions that contraindicated intramuscular influenza vaccination.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

We collected a baseline 9-ml clotted blood sample from enrolled participants, and we used a standardized questionnaire to collect baseline information on demographics, current health status, medical history and medication use. Participants were randomized equally among five equal groups using a permuted block approach with block sizes of 5 and 10, using the statistical software package R. Based on the randomization scheme (Appendix Figure 1), each participant would receive either influenza vaccination or placebo annually in the following schedule for the first four years of the trial in the following schedule: Group 1, placebo injection for all four years; Group 2, placebo for three years followed by influenza vaccination in the fourth year; Group 3, placebo for two years followed by vaccination for two years; Group 4, placebo in the first year and then vaccination for the subsequent three years; and Group 5, vaccination in all four years. All participants would then receive vaccination in the fifth and final year. Allocation to these groups was concealed using REDCap [21]. The influenza vaccine used in our trial is recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) for the northern hemisphere. For the 2020/21 northern hemisphere influenza season, it was formulated to contain 180 mg HA per 0.5-mL dose, with 45 mg HA of each of the following four influenza virus strains: A/Hawaii/70/2019 (H1N1), A/Minnesota/41/2019 (an A/Hong Kong/45/2019-like virus) (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013. In 2021/22 the influenza B strains were unchanged while the influenza A strains were updated to A/Wisconsin/588/2019 (H1N1) and A/Tasmania/503/2020 (an A/Cambodia/e0826360/2020-like virus) (H3N2) (Appendix Table 1). To maintain blinding of participants, we used 0.5 ml saline placebo in syringes prepared in advance and packed the vaccines and placebo doses in numbered boxes according to the

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

randomization scheme. Other than the nurse who conducted the injections, all other study staff were blinded to the study intervention. Following vaccination, we invited participants to return for scheduled follow-up visits at 30 days and 182 days after vaccination for further blood draws. In a subset of participants we arranged for collection of peripheral blood mononuclear cells at baseline, day 7 and day 30, and additional clotted blood samples on days 91 and 273. All participants were invited to report any acute respiratory illnesses. During periods of influenza activity, we planned to implement weekly active illness surveillance, collecting nasal swabs from ill participants for testing by PCR and an additional blood sample 30 days after illness onset. **Ethics** Written informed consent was obtained from all participants. Participants were compensated with a gift voucher worth HK\$100 (US\$13) at each blood draw. The study protocol was approved by the Institutional Review Boards of the University of Hong Kong (ref: UW19-551) and of the University of Chicago Biological Sciences Division (ref: IRB20-0217). Primary and secondary outcomes The primary outcome measure in this trial is the vaccine immunogenicity, measured in terms of antibody titers in hemagglutination-inhibition (HAI) assays or foci reduction neutralization tests (FRNTs) for each vaccine strain. We compared the proportion of participants who achieved the targeted rise in antibody titre against each of the vaccine strains at 30 days. The targeted rise in antibody titre is defined as a four-fold or greater rise in titer, including either a pre-vaccination HAI titer <10 and a post-vaccination HAI titre ≥20 or a pre-vaccination HAI titer ≥10 and at least a four-fold rise in post-vaccination HAI antibody titer. We also assessed

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

the geometric mean titer (GMT) ratios between the various randomized groups against each of the vaccine strains at 30 days and 182 days. HAI assays were completed with A(H1N1) and influenza B viruses; however; we used FRNTs to quantify antibodies against A(H3N2) strains, since some contemporary A(H3N2) strains inefficiently agglutinate red blood cells [10, 22]. Since the FRNT dilution series started at 20 instead of 10 due to the assay design, we defined a targeted rise for antibody titers against A(H3N2) measured by FRNT as a 4-fold rise to a post-vaccination titer of ≥ 40 . Other secondary outcomes specified in the protocol include additional comparisons of antibody titers; analyses of cellular immunity, including transcriptional activity of immune cells; comparisons of adverse reactions after vaccination; and the occurrence of influenza or other acute respiratory illnesses. These secondary outcomes will be addressed in subsequent reports. Of particular note, there was no influenza circulation in Hong Kong between March 2020 and February 2023, which included the first two years of the trial [23]. Only a few influenza virus infections were detected by the local public health laboratory during this period, and they were mostly in arriving travelers and children shedding live attenuated vaccine virus [24, 25]. Laboratory analysis Blood samples were collected in tubes for clotted blood, stored in a refrigerated container at 2-8°C immediately and delivered to the laboratory within two days for further processing. Serum specimens were aliquoted and stored at -80°C prior to subsequent testing. Serum samples were treated with receptor destroying enzyme (RDE) and tested by HAI against the influenza A(H1N1) and B vaccine strains using a standard protocol [26]. For influenza A(H1N1), the vaccine strains were A/Hawaii/70/2019 in 2020/21 (GISAID Accession #

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

EPI397028) and A/Wisconsin/588/2019 (GISAID Accession # EPI404460) in 2021/22. Due to the inability to obtain sufficient volume of cell-grown virus stock, A/Wisconsin/588/2019 was eventually propagated once in eggs. A single mutation D204V was found in the egggrown stock. A comparison of antigenicity using 22 serum samples from five participants showed that assay with the egg-grown stock had slightly higher sensitivity that yielded 2-fold higher titers in 50% of the samples but otherwise showed good correlation with cell-grown stock (Appendix Figure 2). For influenza B, ether-treated egg-grown antigens were used, and the vaccine strains were B/Washington/02/2019 (GISAID Accession # EPI347829) and B/Phuket/3073/2014 (GISAID Accession # EPI168822) in both years. We used a focus reduction neutralization test (FRNT) for the two influenza A(H3N2) vaccine strains A/Hong Kong/45/2019 in 2020/21 and A/Cambodia/e0826360/2020 in 2021/22. A/Hong Kong/45/2019 HA (GISAID Accession # EPI1397376) is identical at the amino acid level to A/Minnesota/41/2019 HA (GISAID Accession # EPI1487157) included in the Flublok for 2020/21 influenza season. However, A/Cambodia/e0826360/2020 HA (GISAID Accession # EPI1837753) differs by a single amino acid substitution (N171K at antigenic site D) from A/Tasmania/503/2020 HA (GISAID Accession # EPI1759269) included in the Flublok for 2021/22 influenza season. Both influenza A(H3N2) virus strains were generated by reverse genetics using A/Puerto Rico/8/1934 internal genes [27]. FRNT assays were completed as previously described [28]. To estimate total binding antibody of specific IgG responses, Enzyme Linked Immunosorbent Assays (ELISAs) were performed with recombinant HA (rHA) of the A(H1N1) vaccine strains A/Hawaii/70/2019 in 2020/21 and A/Wisconsin/588/2019, and the A(H3N2) vaccine strains A/Minnesota/41/2019 and A/Tasmania/503/2020 (Appendix Table 1). The HA stalk

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

monoclonal antibody CR9114 was used as an internal control on each plate. Expression and purification of rHAs and CR9114 was performed as previously described [29]. Sample size justification We aimed to enroll 820 participants into our study. This would permit us to have a sample size of at least 100 participants in each of the five groups at the fourth year of follow-up, allowing for an anticipated drop-out rate of 15% per year without replacement. Most of our outcome measures, including both of our primary outcome measures, are based on geometric mean antibody titers. In year 2, with a target sample size of 139 in each group, we expected to have 80% power to identify 1.6-fold differences in GMT between groups, assuming a standard deviation of log₂(GMT) of 1.8. However, due to disruption in study activities during the COVID-19 pandemic we were unable to reach our target sample size, and as a consequence we updated the protocol to include enrolment of an additional cohort of 530 participants starting in 2021/22 with a similar trial design, with participants randomized across four groups instead of five, and receiving four annual doses of vaccination/placebo as part of the study instead of five. Results from the second cohort with participant enrolment in 2021/22, named DRIVE II, will be reported in due course. For consistency, the present cohort with participant enrolment in 2020/21 is named DRIVE I. Statistical analysis We assessed the proportion of participants who achieved a 4-fold or greater rise in antibody titre against each of the vaccine strains at 30 days, and compared these proportions between the vaccine-vaccine, placebo-vaccine and placebo-placebo groups using Fisher exact tests, pooling the three placebo-placebo groups together. We estimated GMT ratios versus the placebo group at day 30 of year 2 and compared them between first-time vaccines and repeat

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

vaccinees using t-tests on the log-transformed GMT ratios. Confidence intervals were estimated using t distributions. All analyses were conducted in R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria). Data and R syntax will be made available after publication. **RESULTS** From 23 October 2020 through 11 March 2021, 447 individuals were enrolled and received influenza vaccination or placebo according to the randomization scheme, with 88 to 91 individuals in each arm (Figure 1). The median age of participants was 31 years, and 54% were male, with similar characteristics across the five arms (Table 1). None of the participants reported receiving influenza vaccination in the two years prior to the start of the trial, and only 12% reported ever previously receiving influenza vaccination. We randomly selected for laboratory analysis a subset of 15 participants from groups 1-3 (who received placebo in both years), 40 participants from group 4 (placebo followed by vaccination), and 40 participants from group 5 (vaccination in both years), and noted similar characteristics in this subset to the overall participants (Appendix Table 2). Antibody titers increased between days 0 and 30 against each of the vaccine strains, with greater fold increases for first-time vaccinees compared to repeat vaccinees, while the repeat vaccinees had higher antibody titers prior to vaccination in year 2 (Figure 2). At day 30 of year 2, the GMTs were similar in the first-time vaccinees and repeat vaccinees (groups 4 and 5, respectively) for each strain analyzed (Appendix Table 4). While there were statistically significant reductions in the proportion achieving a four-fold greater rise in antibody titer for the repeat vaccinees in year 2 for A(H1N1), B/Victoria and B/Yamagata, there were no

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

statistically significant differences in GMTs at day 30 or the proportions with antibody titers \geq 40 at day 30 for any of the strains (Table 2). The A(H1N1) and A(H3N2) components of the northern hemisphere vaccine were updated between 2020/21 and 2021/22. For each subtype, we examined whether vaccination with one strain increased antibody titers to the other, which is a measure of cross-reactivity or antigenic distance. We focused on the responses in first-time vaccinees in each of the two years (i.e. group 5 in year 1 and group 4 in year 2). For A(H1N1), the year 1 GMT at day 30 was approximately 3.2-fold higher to the 2020/21 vaccine strain (A/Hawaii/70/2019) than to the vaccine strain used the next year (A/Wisconsin/588/2019), consistent with a modest antigenic distance between the two strains (Table 3). For A(H3N2), the fold-difference between the day 30 GMT to the 2020/21 strain (A/Hong Kong/45/2019) and the 2021/22 strain (A/Cambodia/e0826360/2020) was approximately 3.1, also indicating modest antigenic distance. The results in year 2 showed contrasting patterns, in that first-time vaccinees mounted slightly stronger responses to the prior-season vaccine strains than to the current-season vaccine strains. First-time vaccinees in year 2 had slightly higher day 30 GMTs to A(H1N1) A/Wisconsin/588/2019 (the vaccine strain) than did first-time vaccinees receiving A/Hawaii/70/2019 the previous year (60.6 vs. 40), but first-time vaccinees in year 2 had approximately threefold higher titers to the previous year's strain, A/Hawaii/70/2019, than to the strain with which they were vaccinated (180.6 vs. 60.6, respectively) (Table 3). Similarly, first-time vaccinees in year 2 mounted approximately 1.5-fold higher titers to the previous year's H3N2 strain than they did to the H3N2 strain in the vaccine (67.2 to A/Hong Kong/45/2019 and 45.6 to A/Cambodia/e0826360/2020). Similar to the patterns for H1N1,

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

first-time vaccinees had slightly higher absolute post-vaccination titers to the vaccine strain (A/Cambodia/e0826360/2020) compared to individuals vaccinated with A/Hong Kong/45/2019 the previous year (titers of 45.6 vs. 34.7), showing the strain update still led to increased titers to the intended strain. That first-time vaccinees in year 2 mounted higher titers to the prior year's influenza A vaccine strains than to the current vaccine strains might reflect a strong influence of prior immunity, but it could also reflect differences in receptor avidity between the strains. Viruses that bind to cells with lower avidity are more easily neutralized by antibodies compared to viruses that bind with higher avidity, irrespective of antigenic differences [30]. To address this, we measured total HA-specific IgG antibody responses by ELISAs which are not affected by differences in viral receptor binding avidities, to measure antibody binding to the influenza A(H1N1) and A(H3N2) vaccine strains, with results shown in Figure 3 and Table 3. We found that the year 2, geometric mean day 30 antibody levels to the current vaccine strain were similar to or slightly higher than those to the previous vaccine strain in first-time vaccinees, suggesting no disproportionate boosting of prior immunity targeting past strains. That there were no statistically significant differences in the geometric mean post-vaccination antibody levels measured by ELISA between first-time vaccinees in years 1 and 2 suggests the previously reported low HAI and FRNT titers to A/Wisconsin/588/2019 and A/Cambodia/e0826360/2020 thus likely arise from differences in the receptor avidity. The antigenic distances implied by the ELISA data are also smaller and do not show the same asymmetry as before. For instance, the amount of antibody reactive to A/Wisconsin/588/2019 after vaccination with A/Hawaii/70/2019 (group 5, year 1, day 30) was similar to the amount of antibody reactive to A/Hawaii/70/2019 after vaccination with A/Wisconsin/588/2019 (group 4, year 2, day 30) (Table 3). Finally, consistent with the data from the HAI and FRNT

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

assays, there were no statistically significant differences in absolute post-vaccination antibody levels measured by ELISA between first-time and repeat vaccinees in year 2. DISCUSSION In the second year of this five-year trial we identified reduced fold-rises in HAI titers after repeat vaccination for influenza A(H1N1), B/Victoria and B/Yamagata (Figure 2). However, post-vaccination GMTs were similar in repeat vaccinees and first-time vaccinees, indicating that these reduced responses likely would not hinder overall protection assuming that the post-vaccination HAI titer correlates with protection for Flublok [31]. During the study period, public health measures used to contain COVID-19 also prevented the community circulation of influenza [23], and our analysis of antibody titers is therefore unaffected by any potential differences in incidence of influenza virus infections in vaccine versus placebo recipients in the first year of the study that could have occurred if influenza had been circulating. In year 2 of our study we found that repeat and first-time vaccinees also had similar postvaccination GMTs to A(H3N2) measured by FRNT (Figure 2), indicative of similar levels of clinical protection. However, there was no substantial blunting of the fold rises to A(H3N2) in repeat vaccinees. Both groups started with low GMTs to A/Cambodia/e0826360/2020 (H3N2) in year 2 and increased those GMTs approximately 4-fold by 30 days postvaccination (Figure 2, Appendix Table 4). Our ELISA analyses measuring direct antibody binding suggest that the observed differences in HAI and FRNT titers between groups could be due to differences in receptor binding avidities of the viral strains used in our studies.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

Both the A(H1N1) and A(H3N2) vaccine strains were updated between years 1 and 2 of the study, raising opportunities to investigate the cross-reactivity of antibody titers induced by vaccination. The 2020/21 vaccine induced HAI titers to A(H1N1) and FRNT titers to A(H3N2) that were approximately 3-fold lower to the strains used in the 2021/22 vaccine. The suggested benefits of a vaccine update were evidenced by slightly higher titers to those strains among first-time vaccinees the following season compared to titers of vaccinees from the 2020/21 season. However, first-time vaccinees in the 2021/22 season did not have titers that were three-fold lower to strains from the 2020/21 season, as might be expected after vaccination in naïve animals or associated cartographic methods. Instead, individuals vaccinated in 2021/22 had approximately 3-fold and approximately 1.5-fold higher postvaccination GMTs to prior season's A(H1N1) and A(H3N2) vaccine strains. Measuring anti-HA antibody responses with ELISA implied even higher cross-reactivity and limited antigenic distances between viral strains used in successive years. These results suggest a need to interrogate antibody responses through multiple measures and to understand how each relates to protection from infection, disease and transmission. Our study has a number of limitations. To preserve specimens for later longitudinal analyses, we have analyzed a subset of participants from the original study, and thus are limited in the effect sizes we can detect in the present analysis. Future analyses might yield different results. While the strains used in our serologic assays did not have 100% sequence identity with the vaccine strains, the minor genetic differences likely did not affect our major conclusions. Additionally, although the ELISA data suggest that antibody responses were comparable in magnitude between year 1 and 2 influenza A vaccine strains, at present we cannot conclude whether the contrasting HAI and FRNT results reflect strain-specific differences in receptor binding avidity, neutralization potential, and/or the relative immunogenicity of the stalk and

other epitopes that are poorly measured by HAI. Understanding the roles of these factors is an important area for further work [32].

In conclusion, our randomized clinical trial of repeat influenza vaccination has found that repeat vaccination can be associated with reduced fold changes in antibody titers, but our preliminary results show no evidence of reduced post-vaccination mean titers, consistent with similar levels of protection after vaccination regardless of vaccination history. The apparently low immunogenicity of influenza A vaccine strains in 2021/22 relative to the prior year may reflect increases in receptor avidity of updated vaccine strains and deserves further study.

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

ACKNOWLEDGMENTS The authors thank Suk Yee Chan, Tin Kin Chau, Trushar Jeevan, Pat Kaewpreedee, Ida Lam, Erica Lau, Kelly Lee, Maggie Lo, Charlie Man, Tiffany Ng, Yammy Ng, Yvonne Ng, Eunice Shiu, Lewis Siu, Tiffany Tavares, Ivan Tsai, Lilly Wang, Angel Wong, Irene Wong, Miyuki Wong, Phebe Yeung, and Zoe Xiao for technical support, and Julie Au and Ada Lee for administrative support. **FUNDING** This project was supported by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services (grant no. U01 AI153700 and contract nos. 75N93021C00015 and 75N93021C00016), and the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government. BJC is supported by an RGC Senior Research Fellowship (grant number: HKU SRFS2021-7S03). POTENTIAL CONFLICTS OF INTEREST B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche and Sanofi Pasteur. S.C. has consulted for Seqirus. S.E.H. is a coinventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novayax, and Merck. The authors report no other potential conflicts of interest.

REFERENCES

- 399 1. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United
- 400 States During the 2018-2019 Influenza Season. Clin Infect Dis **2020**; 71:e368-e76.
- 401 2. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by
- subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect
- 403 Dis **2016**; 16:942-51.
- 3. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of Repeated Vaccination on
- Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. Clin Infect Dis
- 406 **2014**; 59:1375-85.
- 4. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic
- 408 Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-
- 409 2015 Season. Clin Infect Dis **2016**; 63:21-32.
- 5. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.
- Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert
- 412 Rev Vaccines **2017**; 16:1-14.
- 6. Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on
- influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med **2019**;
- 415 17:9.
- 7. Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. Does repeated influenza
- vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir
- 418 Med **2023**; 11:27-44.
- 419 8. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.
- 420 Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-
- Dose Inactivated Influenza Vaccine in Older Adults. Clin Infect Dis **2016**; 62:1092-9.

- 422 9. Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated
- 423 influenza vaccination among healthcare personnel on serum hemagglutinin inhibition
- antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine **2016**;
- 425 34:981-8.
- 426 10. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a
- 427 glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
- 428 Proc Natl Acad Sci U S A **2017**; 114:12578-83.
- 429 11. Gouma S, Zost SJ, Parkhouse K, et al. Comparison of Human H3N2 Antibody Responses
- Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines
- 431 During the 2017-2018 Season. Clin Infect Dis **2020**; 71:1447-53.
- 12. Leung VKY, Fox A, Carolan LA, et al. Impact of prior vaccination on antibody response
- and influenza-like illness among Australian healthcare workers after influenza vaccination in
- 434 2016. Vaccine **2021**; 39:3270-8.
- 13. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual
- 436 influenza vaccination. PNAS **1999**; 96:14001-6.
- 14. Skowronski DM, Chambers C, De Serres G, et al. Serial Vaccination and the Antigenic
- Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2)
- 439 Epidemics in Canada, 2010-2011 to 2014-2015. J Infect Dis **2017**; 215:1059-99.
- 15. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin:
- Separating Good From Evil. J Infect Dis **2017**; 215:1782-8.
- 16. Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines
- 443 (Basel) **2018**; 6.
- 17. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza
- vaccine. Influenza Other Respir Viruses **2008**; 2:211-9.

- 446 18. Yang LP. Recombinant trivalent influenza vaccine (flublok((R))): a review of its use in
- the prevention of seasonal influenza in adults. Drugs **2013**; 73:1357-66.
- 19. Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of
- Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults
- 450 >/= 50 years of age. Vaccine **2015**; 33:6622-8.
- 451 20. Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok
- in the prevention of seasonal influenza in adults. Ther Adv Vaccines **2015**; 3:97-108.
- 453 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- data capture (REDCap)--a metadata-driven methodology and workflow process for providing
- translational research informatics support. J Biomed Inform **2009**; 42:377-81.
- 456 22. Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution,
- and evaluation. Hum Vaccin Immunother **2018**; 14:1840-7.
- 458 23. Xiong W, Cowling BJ, Tsang TK. Influenza Resurgence after Relaxation of Public
- Health and Social Measures, Hong Kong, 2023. Emerg Infect Dis **2023**; 29:2556-9.
- 460 24. Mak GCK, Lau SSY, Lam ETK, Ng KHL, Chan RCW. Domination of influenza vaccine
- virus strains in Hong Kong, 2021. Influenza Other Respir Viruses **2022**; 16:1191-3.
- 462 25. Mak GCK, Lau SSY, Wong KKY, Lau AWL, Hung DLL. Low prevalence of seasonal
- influenza viruses in Hong Kong, 2022. Influenza Other Respir Viruses **2023**; 17:e13123.
- 464 26. WHO Global Influenza Surveillance Network. WHO global influenza surveillance
- network: Manual for the laboratory diagnosis and virological surveillance of influenza.
- 466 Available at:
- 467 https://iris.who.int/bitstream/handle/10665/44518/9789241548090 eng.pdf?sequence=1.
- 468 27. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of
- Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015
- 470 Influenza Season. Cell Rep **2015**; 12:1-6.

- 471 28. Gouma S, Weirick M, Hensley SE. Antigenic assessment of the H3N2 component of the
- 472 2019-2020 Northern Hemisphere influenza vaccine. Nat Commun **2020**; 11:2445.
- 29. Bolton MJ, Santos JJS, Arevalo CP, et al. IgG3 subclass antibodies recognize
- antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent
- 475 binding. Proc Natl Acad Sci U S A **2023**; 120:e2216521120.
- 476 30. Fazekas S, Groth S. Antigenic, Adaptive and Adsorptive Variants of the Influenza a
- Hemagglutinin. In: Laver, W.G., Bachmayer, H., Weil, R. (eds) The Influenza Virus
- Hemagglutinin. Topics in Infectious Diseases, vol 3. Springer, Vienna.
- 479 <u>https://doi.org/10.1007/978-3-7091-4130-4_3</u>. In: Laver WG, Bachmayer H, Weil R, eds.
- 480 The Influenza Virus Hemagglutinin Topics in Infectious Diseases, vol 3. Vienna: Springer,
- 481 **1978**.

- 482 31. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant
- hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized,
- placebo-controlled trial. Vaccine **2011**; 29:7733-9.
- 485 32. Loes AN, Tarabi RAL, Huddleston J, et al. High-throughput sequencing-based
- neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1
- 487 influenza strains. bioRxiv **2024**:2024.03.08.584176.

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

FIGURE LEGENDS Figure 1. Study flow chart showing participant enrolment into the study, randomization into five groups, interventions received, and follow up. Footnote: *The random samples were selected from participants who provided serum samples at these five timepoints: year 1 day 0, day 30 and day 182, and year 2 day 0 and day 30. Figure 2. Antibody titers at various timepoints measured by hemagglutination inhibition assay for influenza A(H1N1) and B, and by focus reduction neutralization test for influenza A(H3N2). Measured titers are plotted for each group at 0, 30 and 182 days post-vaccination of year 1 and at 0 and 30 days post-vaccination of year 2, and lines represent the geometric mean titers at each timepoint. Data from group 5, receiving vaccine in both years, are shown in red. Data from group 4, receiving placebo in year 1 and vaccine in year 2, are shown in blue. Data from the other groups, receiving placebo in both years, are shown in gray. Figure 3. Antibody levels at various timepoints measured by enzyme-linked immunosorbent assay for influenza A(H1N1) and A(H3N2). Measured titers are plotted at 0 and 30 days postvaccination in years 1 and 2, and lines represent the geometric mean antibody levels at each timepoint. Data from group 5, receiving vaccine in both years, are shown in red. Data from group 4, receiving placebo in year 1 and vaccine in year 2, are shown in blue. Data from the other groups, receiving placebo in both years, are shown in gray.

Table 1. Characteristics of participants randomized to different vaccination strategies

Characteristic	Randomized allocation to receipt of placebo (P) or influenza vaccination (V)							
	in five consecutive years							
	Group 1	Group 2	Group 3	Group 4	Group 5			
	P-P-P-V	P-P-P-V-V	P-P-V-V-V	P-V-V-V	V-V-V-V			
	(n=90)	(n=91)	(n=88)	(n=90)	(n=88)			
Age at								
randomization								
18-25 years	27 (30%)	27 (30%)	34 (39%)	22 (24%)	20 (23%)			
26-35 years	32 (36%)	32 (35%)	28 (32%)	34 (38%)	34 (39%)			
36-45 years	31 (34%)	32 (35%)	26 (30%)	34 (38%)	34 (39%)			
Male sex	48 (53%)	60 (66%)	42 (48%)	46 (51%)	44 (50%)			
Reported receipt of influenza vaccination in	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)			
the two years prior to the trial								
Reported ever receiving influenza	11 (12%)	11 (12%)	15 (17%)	9 (10%)	9 (10%)			
vaccination								
prior to the trial								

Table 2. Antibody responses to influenza vaccination and placebo in year 2 of the trial, with 95% confidence intervals. Antibody responses were measured by HAI for influenza A(H1N1) and B, and by FRNT for influenza A(H3N2).

(n=15) (n=40) (n=40) group 5 (V and	Outcome and Virus	Groups 1-3	Group 4	Group 5	p-value	
## Armibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1) (4.0, 15) (3.1, 10) A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 (0.4, 9.1) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 1.142 (0.4, 9.1) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 1.142 (0.4, 9.1) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 1.142 (0.79, 2.55) B/Washington/02/2019 - 1.142 (0.79, 2.55) B/Washington/02/2019 - 1.42 (0.79, 2.55) B/Washington/02/2019 - 1.42 (0.79, 2.55) B/Washington/02/2019 - 1.42 (0.79, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)		(P-P)	(P-V)	(V-V)	comparing	
Proportion with ≥4-fold rise in antibody titer from day 0 to day 30 post-vaccination* A/Wisconsin/588/2019 13% 78% 45% 0.4 (H1N1) (1.6%, 40%) (62%, 89%) (29%, 62%) A/Cambodia/e0826360/2020 0% 60% 53% 0.6 (H3N2) (0%, 21%) (43%, 75%) (36%, 68%) B/Washington/02/2019 6.7% 70% 25% <0.1 (0.2%, 32%) (53%, 83%) (13%, 41%) B/Phuket/3073/2013 0% 68% 10% <0.3 (0%, 22%) (51%, 81%) (0.3%, 24%) Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1) (4.0, 15) (3.1, 10) A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 0.6 (H1N1) (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 0.7 A/Wisconsin/588/2019 - 0.73 A/Cambodia/e0826360/2020 - 0.68 0.7 B/Washington/02/2019 - 0.68 0.7 B/Wash		(n=15)	(n=40)	(n=40)	group 5 (V-V)	
Proportion with ≥4-fold rise in antibody titer from day 0 to day 30 post-vaccination* A/Wisconsin/588/2019 13% 78% 45% 0.9 (H1N1) (1.6%, 40%) (62%, 89%) (29%, 62%) A/Cambodia/e0826360/2020 0% 60% 53% 0 (H3N2) (0%, 21%) (43%, 75%) (36%, 68%) 0.9 B/Washington/02/2019 6.7% 70% 25% <0.0 (0.2%, 32%) (53%, 83%) (13%, 41%) <0.0 B/Phuket/3073/2013 0% 68% 10% <0.0 (0%, 22%) (51%, 81%) (0.3%, 24%) <0.0 Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H3N2) (2.4, 6.4) (3.6, 8.8) 8 B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) 6 B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) 0.73 0.0 A/Wisconsin/588/2019					and group 4	
A/Wisconsin/588/2019 13% 78% 45% 0.4 (H1N1) (1.6%, 40%) (62%, 89%) (29%, 62%) A/Cambodia/e0826360/2020 0% 60% 53% 0 (H3N2) (0%, 21%) (43%, 75%) (36%, 68%) B/Washington/02/2019 6.7% 70% 25% <0.6 (0.2%, 32%) (53%, 83%) (13%, 41%) B/Phuket/3073/2013 0% 68% 10% <0.3 (0%, 22%) (51%, 81%) (0.3%, 24%) Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1) (4.0, 15) (3.1, 10) A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 0 (H1N1) (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 0 (H3N2) (0.79, 2.55) B/Washington/02/2019 - 1.42 0 (H3N2) (0.79, 2.55) B/Washington/02/2019 - 0.68 0 (0.36, 1.29)					(P-V)	
(H1N1)	Proportion with ≥4-fold rise in	antibody titer fr	om day 0 to day 3	30 post-vaccinatio	n*	
A/Cambodia/e0826360/2020 0% 60% 53% 0 (H3N2) (0%, 21%) (43%, 75%) (36%, 68%) B/Washington/02/2019 6.7% 70% 25% <0.0 (0.2%, 32%) (53%, 83%) (13%, 41%) B/Phuket/3073/2013 0% 68% 10% <0.0 (0%, 22%) (51%, 81%) (0.3%, 24%) Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1) (4.0, 15) (3.1, 10) A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 (0.37, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)	A/Wisconsin/588/2019	13%	78%	45%	0.005	
(H3N2)	(H1N1)	(1.6%, 40%)	(62%, 89%)	(29%, 62%)		
B/Washington/02/2019 6.7% 70% 25% <0.4 (0.2%, 32%) (53%, 83%) (13%, 41%) B/Phuket/3073/2013 0% 68% 10% <0.4 (0%, 22%) (51%, 81%) (0.3%, 24%) Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1) (4.0, 15) (3.1, 10) A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 (0.79, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)	A/Cambodia/e0826360/2020	0%	60%	53%	0.65	
(0.2%, 32%) (53%, 83%) (13%, 41%)	(H3N2)	(0%, 21%)	(43%, 75%)	(36%, 68%)		
B/Phuket/3073/2013 0% 68% 10% <0.4 (0%, 22%) (51%, 81%) (0.3%, 24%) Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1) (4.0, 15) (3.1, 10) A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 (H1N1) (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 (H3N2) (0.79, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)	B/Washington/02/2019	6.7%	70%	25%	< 0.001	
Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1)		(0.2%, 32%)	(53%, 83%)	(13%, 41%)		
Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group A/Wisconsin/588/2019 - 7.64 5.59 (H1N1)	B/Phuket/3073/2013	0%	68%	10%	< 0.001	
A/Wisconsin/588/2019 - 7.64 5.59 (H1N1)		(0%, 22%)	(51%, 81%)	(0.3%, 24%)		
(H1N1)	Antibody GMT ratio at day 30	post-vaccination	compared to P-F	reference group		
A/Cambodia/e0826360/2020 - 3.97 5.65 (H3N2)	A/Wisconsin/588/2019	-	7.64	5.59	-	
(H3N2) (2.4, 6.4) (3.6, 8.8) B/Washington/02/2019 - 4.14 2.83 (1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 (0.37, 1.43) A/Cambodia/e0826360/2020 - 0.68 (0.36, 1.29)	(H1N1)		(4.0, 15)	(3.1, 10)		
B/Washington/02/2019 - 4.14 2.83	A/Cambodia/e0826360/2020	-	3.97	5.65	-	
(1.9, 9.2) (1.3, 6.0) B/Phuket/3073/2013	(H3N2)		(2.4, 6.4)	(3.6, 8.8)		
B/Phuket/3073/2013 - 4.65 3.91 (2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 - 0.73 (0.37, 1.43) A/Cambodia/e0826360/2020 - 1.42 (0.79, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)	B/Washington/02/2019	-	4.14	2.83	-	
(2.4, 9.1) (2.0, 7.8) Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 0.73 (0.37, 1.43) A/Cambodia/e0826360/2020 1.42 (0.79, 2.55) B/Washington/02/2019 0.68 (0.36, 1.29)			(1.9, 9.2)	(1.3, 6.0)		
Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group A/Wisconsin/588/2019 0.73 0 (H1N1)	B/Phuket/3073/2013	-	4.65	3.91	-	
A/Wisconsin/588/2019 0.73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			(2.4, 9.1)	(2.0, 7.8)		
(H1N1) (0.37, 1.43) A/Cambodia/e0826360/2020 1.42 (0.79, 2.55) B/Washington/02/2019 0.68 (0.36, 1.29)	Antibody GMT ratio at day 30	post-vaccination	compared to P-V	⁷ reference group		
A/Cambodia/e0826360/2020 1.42 0 (H3N2) (0.79, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)	A/Wisconsin/588/2019	-	-	0.73	0.36	
(H3N2) (0.79, 2.55) B/Washington/02/2019 - 0.68 (0.36, 1.29)	(H1N1)			(0.37, 1.43)		
B/Washington/02/2019 0.68 (0.36, 1.29)		-	-		0.23	
B/Washington/02/2019 0.68 (0.36, 1.29)						
(0.36, 1.29)		-	-	, , ,	0.23	
	C					
B/Pnuket/30/3/2013 0.84	B/Phuket/3073/2013	-	_	0.84	0.42	

(0.55, 1.29)

Proportion with antibody titer	≥40 at day 30 po	st-vaccination		
A/Wisconsin/588/2019	20%	78%	78%	1.00
(H1N1)	(4.3%, 48%)	(62%, 89%)	(62%, 89%)	
A/Cambodia/e0826360/2020	13%	75%	85%	0.40
(H3N2)	(1.7%, 40%)	(59%. 87%)	(70%, 94%)	
B/Washington/02/2019	53%	88%	88%	1.00
	(26%, 79%)	(73%, 96%)	(73%, 96%)	
B/Phuket/3073/2013	87%	100%	98%	1.00
	(60%, 98%)	(91%, 100%)	(87%, 100%)	

*For influenza A(H1N1) and B this was defined as either a pre-vaccination antibody titer <10 and a post-vaccination antibody titre \geq 20, or a pre-vaccination antibody titer \geq 10 and at least a four-fold rise in post-vaccination antibody titer. For influenza A(H3N2) this was defined as either a pre-vaccination antibody titer <20 and a post-vaccination antibody titre \geq 40, or a pre-vaccination antibody titer \geq 20 and at least a four-fold rise in post-vaccination antibody titer.

Table 3. Geometric mean antibody levels 30 days post-vaccination for participants receiving vaccination for the first time in the study

Study arm and	A(H1N1)		A(H	3N2)	B/Vic	B/Yam
year						
	A/Hawaii/70/2019	A/Wisconsin/588/2019	A/Minnesota/41/2019	A/Tasmania/503/2020	B/Washington/02/2019	B/Phuket/3073/2013
Assay	HAI	HAI^{\ddagger}	FRNT*	$FRNT^{\dagger}$	HAI	HAI
Group 5 in Year 1	127.7	40.0	107.4	34.7	61.7	273.8
Group 4 in Year 2	180.6	60.6	67.2	45.6	72.1	234.3
Assay	ELISA	ELISA	ELISA	ELISA		
Group 5 in Year 1	14400	5920	51100	34600	-	-
Group 4 in Year 2	19200	18000	48600	68500	-	-

Cells in bold indicate homologous responses to vaccine strains. Values for all three assays are

525

529

531

532

533

FRNT assay

⁵²⁷ antibody titers.

[‡] This virus contained an egg adaptation, D187V.

 $[*] The \ similar \ virus \ A/Hong \ Kong/45/2019 \ was \ used in \ place \ of \ A/Minnesota/41/2019 \ for \ the \ FRNT$

⁵³⁰ assay

[†] The similar virus A/Cambodia/e0826360/2020 was used in place of A/Tasmania/503/2020 for the





